SSStuart G. Silverman

Stuart G. Silverman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stuart G. Silverman has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cryoablation of Liver Tumors

    by Jennifer Huang, Stuart G. Silverman, Paul B. Shyn

  • Diagnostic Accuracy of Bosniak v2019 for Predicting Cancer and Unfavorable Histology in Class III–IV Cystic Renal Masses

    by Justin R. Tse, Shokoufeh Khalatbari, Matheos Yosef, Chen Abitbol, Asser M. Abou Elkassem, Emin Albayrak, Ronaldo Hueb Baroni, Rajesh Bhayana, Jennie J. Cao, Fernando Morbeck Almeida Coelho, et al.

    This multicenter multinational study demonstrated that Bosniak classification version 2019 can be used to stratify the probability of cancer and cancer with unfavorable histologic features; nodule size was strongly associated with unfavorable histologic features.


  • Percutaneous Cryoablation Versus Microwave Ablation for Hepatocellular Carcinoma: Comparative Study of Safety and Oncologic Outcomes

    by David-Dimitris Chlorogiannis, Sharath K. Bhagavatula, Stuart G. Silverman, Borna E. Dabiri, Kemal Tuncali, Vincent M. Levesque, Ravi V. Gottumukkala, Zhou Lan, Paul B. Shyn

    Percutaneous image-guided cryoablation and microwave ablation demonstrated similar safety and oncologic outcomes for treatment of hepatocellular carcinoma.

  • Renal Oncocytic Neoplasms: Review of Classification Updates, Imaging, and Management

    by Maame Akua Akobeng, Rajesh Bhayana, Murray Di Loreto, Myles Taffel, Sungmin Woo, Sree Harsha Tirumani, Krishna Shanbhogue, Susan Prendeville, Khaled Elsayes, Nicola Schieda, et al.

    Renal oncocytic neoplasms pose diagnostic challenges due to overlapping imaging features, and radiologists should be aware of recent classification updates, imaging findings, biopsy limitations, and evolving management strategies.


  • Assessing the malignancy rate of adrenal nodules in patients with a history of cancer: factors associated with adrenal metastases

    by Amir A. Satani, Ronilda Lacson, Stuart G. Silverman, William W. Mayo-Smith, Ryan Chung, Ramin Khorasani, Daniel I. Glazer

    Objectives To determine malignancy rate of adrenal nodules in patients with a history of cancer and identify factors predictive of adrenal metastases. Methods This Institutional Review Board-approved, retrospective study was performed 1/1/2010-12/31/2020 at an academic health system. Cancer registry data and natural language processing identified patients with a history of extra-adrenal malignancy who had undergone contrast-enhanced abdominal CT or MRI and had adrenal nodules ≥ 1 cm. A power calculation based on previously published prevalence of malignancy in adrenal nodules determined the minimum number of patients. The reference standard used for diagnosis was pathology when available, or imaging follow-up ≥ 1 year. Cancer type, presence/absence of extra-adrenal metastatic disease on index scan, and size of the adrenal nodule were extracted from the electronic health record. These factors were correlated with adrenal nodule outcome (benign or metastatic) using univariate and multivariable logistic regression analyses. Results The cohort included 420 patients (219 female; mean age 71.4 years [standard deviation 11.1]). Overall metastatic adrenal nodule rate was 15.7% (66/420). Patients with extra-adrenal metastatic disease were more likely to have metastatic adrenal nodules compared to those with an isolated adrenal nodule (24.5% [37/151] vs. 10.8% [29/269]; p ≤ 0.001). Adrenal metastases were most common in patients with melanoma (50%, 10/20) and lung cancer (32%, 24/75). Metastatic rate increased with nodule size 2–4 cm (Odds Ratio [OR] 1.98) and > 4 cm (OR 3.25). In patients with an isolated adrenal nodule, primary malignancy (lung cancer: OR 10.80; melanoma: OR 32.91) and size (2–4 cm: OR 5.14, > 4 cm: OR 9.69) were associated with increased risk of metastases. Conclusion In a cohort of patients with a history of any type of malignancy, almost 90% of isolated adrenal nodules were benign. However, a history of lung cancer, melanoma, or lesion size ≥ 2 cm significantly increased the risk of adrenal metastases.

  • An Interventional Radiology Method for In Situ Assessments of Cancer Drug Response: Preclinical Development, Feasibility, and Safety

    by Sharath K. Bhagavatula, Ryan Reichert, Sebastian W. Ahn, Grace Foley, Zuzana Tatarova, Juraj Jakubik, Christine A. Dominas, Courtney Marlin, Natalie Azzolini, Ellen Maloney, et al.

    Interventional placement and retrieval of implantable microdevices was technically feasible and safe in a rabbit hindlimb tumor model.


  • In Pursuit of KI-RADS: Toward a Single, Evidence-based Imaging Classification of Renal Masses

    by Stuart G. Silverman, Ivan Pedrosa, Nicola Schieda, Vitaly Margulis, Payal Kapur, Matthew S. Davenport

    This review describes the rationale, challenges, and research needed to create a Kidney Imaging Reporting and Data System that predicts both the likelihood of cancer and the likelihood of aggressive cancer.


  • Cryoablation of Liver Tumors

    by Jennifer Huang, Stuart G. Silverman, Paul B. Shyn


  • Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis

    by Jessie L. Chai, Lauren A. Roller, Xiaoyang Liu, Zhou Lan, Matthew Mossanen, Stuart G. Silverman, Atul B. Shinagare

    Purpose To assess VIRADS performance and inter-reader agreement for detecting muscle-invasive bladder cancer (MIBC) following transurethral resection of bladder tumor (TURBT). Methods An IRB-approved, HIPAA-compliant, retrospective study from 2016 to 2020 included patients with bladder urothelial carcinoma who underwent MRI after TURBT, and cystectomy within 3 months without post-MRI treatments. Three radiologists blinded to pathology results independently reviewed MR images and assigned a VI-RADS score. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of VI-RADS were assessed for diagnosing MIBC using VI-RADS scores ≥ 3 and ≥ 4. Inter-reader agreement was assessed using Gwet’s agreement coefficient (AC) and percent agreement. Results The cohort consisted of 70 patients (mean age, 68 years ± 11 [SD]; range 39–85; 58 men) and included 32/70 (46%) with MIBC at cystectomy. ROC analysis revealed an AUC ranging from 0.67 to 0.77 and no pairwise statistical difference between readers (p-values, 0.06, 0.08, 0.97). Percent sensitivity, specificity, PPV, NPV and accuracy for diagnosing MIBC for the three readers ranged from 81.3–93.8, 36.8–55.3, 55.6–60.5, 77.3–87.5, and 62.9–67.1 respectively for VI-RADS score ≥ 3, and 78.1–81.3, 47.4–68.4, 55.6–67.6, 72.0–78.8 and 61.4–72.9 respectively for VI-RADS score ≥ 4. Gwet’s AC was 0.63 [95% confidence interval (CI): 0.49,0.78] for VI-RADS score ≥ 3 with 79% agreement [95% CI 72,87] and 0.54 [95%CI 0.38,0.70] for VI-RADS score ≥ 4 with 76% agreement [95% CI 69,84]. VIRADS performance was not statistically different among 31/70 (44%) patients who received treatments prior to MRI (p ≥ 0.16). Conclusion VI-RADS had moderate sensitivity and accuracy but low specificity for detection of MIBC following TURBT, with moderate inter-reader agreement. Graphical abstract


  • Clinical indications, safety, and effectiveness of percutaneous image-guided adrenal mass biopsy: an 8-year retrospective analysis in 160 patients

    by Matthew P. Schenker, Stuart G. Silverman, William W. Mayo-Smith, Ramin Khorasani, Daniel I. Glazer

    Purpose To assess indications, safety, and effectiveness of percutaneous adrenal mass biopsy in contemporary practice. Methods This institutional review board-approved, retrospective study included all patients undergoing percutaneous image-guided adrenal mass biopsies at an academic health system from January 6, 2015, to January 6, 2023. Patient demographics, biopsy indications, mass size, laboratory data, pathology results, and complications were recorded. Final diagnoses were based on pathology or ≥ 1 year of imaging follow-up when biopsy specimens did not yield malignant tissue. Test performance calculations excluded repeat biopsies. Continuous variables were compared with Student’s t test, dichotomous variables with chi-squared test. Results A total of 160 patients underwent 186 biopsies. Biopsies were indicated to diagnose metastatic disease (139/186; 74.7%), for oncologic research only (27/186; 14.5%), diagnose metastatic disease and oncologic research (15/186; 8%), and diagnose an incidental adrenal mass (5/186; 2.7%). Biopsy specimens were diagnostic in 154 patients (96.3%) and non-diagnostic in 6 (3.8%). Diagnostic biopsies yielded malignant tissue (n = 136), benign adrenal tissue (n = 12), and benign adrenal neoplasms (n = 6) with sensitivity = 98.6% (136/138), specificity = 100% (16/16), positive predictive value = 100% (136/136), and negative predictive value = 88.9% (16/18). Adverse events followed 11/186 procedures (5.9%) and most minor (7/11, 63.6%). The adverse event rate was similar whether tissue was obtained for clinical or research purposes (10/144; 6.9% vs. 1/42; 2.4%, p = 0.27), despite more specimens obtained for research (5.8 vs. 3.7, p < 0.001). Conclusion Percutaneous adrenal mass biopsy is safe, accurate, and utilized almost exclusively to diagnose metastatic disease or for oncologic research. The negative predictive value is high when diagnostic tissue samples are obtained. Obtaining specimens for research does not increase adverse event risk. Graphical Abstract